Proteomics

Dataset Information

0

Determining MELK inhibitor specificity using MIB/MS

ABSTRACT: The key objectives of this study were to evaluate the selectivity profiles of three MELK inhibitors, 8a, HTH, and OTS, using a cell-based assay, in order to identify a highly selective inhibitor to subsequently investigate MELK function. To this end, we utilized a chemical proteomics approach called multiplexed kinase inhibitor beads/mass spectrometry (MIB/MS) to characterize the selectivity of these MELK inhibitors in TNBC cells.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Laura Herring  

LAB HEAD: Lee M. Graves

PROVIDER: PXD016022 | Pride | 2020-01-09

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20180623_PC463-Graves-McDonald_Sample1.raw Raw
20180623_PC463-Graves-McDonald_Sample2.raw Raw
20180623_PC463-Graves-McDonald_Sample3.raw Raw
20180623_PC463-Graves-McDonald_Sample4.raw Raw
20180623_PC463-Graves-McDonald_Sample5.raw Raw
Items per page:
1 - 5 of 22
altmetric image

Publications

Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.

McDonald Ian M IM   Grant Gavin D GD   East Michael P MP   Gilbert Thomas S K TSK   Wilkerson Emily M EM   Goldfarb Dennis D   Beri Joshua J   Herring Laura E LE   Vaziri Cyrus C   Cook Jeanette Gowen JG   Emanuele Michael J MJ   Graves Lee M LM  

The Journal of biological chemistry 20200102 8

The maternal embryonic leucine zipper kinase (MELK) has been implicated in the regulation of cancer cell proliferation. RNAi-mediated MELK depletion impairs growth and causes G<sub>2</sub>/M arrest in numerous cancers, but the mechanisms underlying these effects are poorly understood. Furthermore, the MELK inhibitor OTSSP167 has recently been shown to have poor selectivity for MELK, complicating the use of this inhibitor as a tool compound to investigate MELK function. Here, using a cell-based p  ...[more]

Similar Datasets

Proteomics Kinome Profiling of Gastrointestinal Stromal Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies Wee1 as a Candidate Therapeutic Target
2021-09-09 | PXD020720 | Pride
Proteomics RAPID RESISTANCE TO BET INHIBITORS IS MEDIATED BY FGFR1 IN GLIOBLASTOMA
2024-06-16 | PXD043214 | Pride
Proteomics Determining the KRAS-regulated kinome in PDAC
2022-02-17 | PXD025819 | Pride
Proteomics MIB/MS determines SCH772984 is a selective ERK1/2 inhibitor in pancreatic cancer cells
2024-05-29 | PXD043585 | Pride
Proteomics Kinase Selectivity Profiling of anti-MRSA Diarylimidazoles in HEK293 Cells
2024-01-26 | PXD040208 | Pride
Proteomics Kinome profiling: cabozantinib treatment in a mouse model of plexiform neurofibroma
2020-11-19 | PXD019138 | Pride
Proteomics Effect of PTEN knockout on dabrafenib-trametinib treatment in A375 melanoma cells - replicate 1
2024-04-23 | PXD033866 | Pride
Proteomics Effect of PTEN knockout on dabrafenib-trametinib treatment in A375 melanoma cells - replicate 2
2024-04-23 | PXD033921 | Pride
Proteomics Kinome profiling of shControl and shFANCA HL60 cells treated with volasertib
2024-11-21 | PXD048014 | Pride
Proteomics Effect of oxygen tension on MMTV-PyMT tumor cell kinome
2024-05-08 | PXD046005 | Pride